CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 enrolled
Drug / intervention
VERDYE powder for solution for injection 25 mgdrug
Likely dose
VERDYE powder for solution for injection 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05419947
NCT05419947Phase 4Completed

Randomized Clinical Trial for the Optimization of Indocyanine Green Administration in Near-infrared Fluorescent Cholangiography During Laparoscopic Cholecystectomy.

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León·interventional·Posted Jun 15, 2022·Updated Jun 17, 2025

In Brief

A Phase 4 clinical trial evaluating VERDYE powder for solution for injection 25 mg for Laparoscopic Cholecystectomy. Completed, enrolled 200 participants across 2 sites.

Detailed Summary

Laparoscopic cholecystectomy is one of the most performed surgical procedures worldwide. One of its most serious complications is injury to the main bile duct, with an incidence of less than 1%. There are different surgical strategies that try to reduce this complication, with indocyanine green fluorescence cholangiography being one of the most recent to appear. This technique is becoming a great tool during laparoscopic cholecystectomy. Despite the great rise of the procedure, today there is a great disparity in the administration protocols of indocyanine green during the procedure. Goals. The main objective of the study is to analyze whether there are differences between different types of doses and administration intervals of indocyanine green to obtain quality fluorescent cholangiography during laparoscopic cholecystectomy. In addition, the factors that influence the results of the technique will be sought.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJun 15, 2022
Enrollment StartJun 20, 2022
Primary CompletionMay 16, 2023
Study CompletionOct 24, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.0 years ago

Interventions

VERDYE powder for solution for injection 25 mgdrug

Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.